ArticleInternational dental journal2026
Waterpipe Smoke-Induced N6-Methyladenosine Modification Promotes the Progression of Oral Squamous Cell Carcinoma.
Article in International dental journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWaterpipe smoking (WPS) is increasingly recognized as a risk factor for oral squamous cell carcinoma (OSCC), but the molecular mechanisms are still not well understood. Emerging evidence emphasizes the role of m6A RNA methylation in cancer development and progression, with METTL3 serving as a key regulator of m6A. This study investigates METTL3 expression and its impact on epithelial-mesenchymal transition (EMT) and cell proliferation in OSCC exposed to waterpipe smoke condensate (WPSC).
methodsCAL27 OSCC cells were treated with WPSC, and the expressions of METTL3, its target oncogene HMGA2, and EMT markers were analysed using quantitative PCR and Western blotting. Cell proliferation, clonogenic assays, and METTL3 inhibition were conducted for functional studies. METTL3 expression was evaluated in both primary and metastatic OSCC tissues and further validated using TCGA-OSCC datasets. Protein-protein interactions and functional enrichment analyses were also performed.
resultsWPSC treatment significantly increased METTL3 and its target HMGA2, as well as the expression of EMT markers in OSCC cells (P < .001). Inhibiting METTL3 suppressed WPSC-induced HMGA2 expression, EMT, and clonogenic potential. Patient tissues and TCGA-OSCC dataset analyses verified that METTL3 was highly expressed in metastatic and smoking-related OSCCs (P < .001). Functional enrichment results suggest METTL3 plays a critical role in tumour progression. High HMGA2 expression is correlated with poor prognosis and resistance to PD-L1 immunotherapy.
conclusionsWPSC promotes OSCC progression by increasing METTL3 levels, which enhances HMGA2 expression and facilitates EMT. Targeting METTL3 could be an effective therapeutic approach and a useful biomarker for metastatic, tobacco-related OSCC. CLINICAL RELEVANCE: Elevated levels of METTL3 induced by waterpipe smoke lead to OSCC progression via HMGA2 and EMT, highlighting METTL3 as a potential biomarker and therapeutic target in OSCC caused by smoking.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.